Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
240.4 USD | -1.68% |
|
-5.40% | +3.92% |
Jul. 02 | Evercore ISI Cuts Price Target on Danaher to $260 From $266, Maintains Outperform Rating | MT |
Jun. 27 | FDA Approves Danaher Unit's Rapid Test for Hepatitis C | DJ |
Evolution of the average Target Price on Danaher Corporation
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
![Consensus](/images/consensus_flch.gif)
Consensus detail
Consensus revision (last 18 months)
Analysts covering Danaher Corporation
Raymond James | |
HSBC | |
TD Cowen | |
Barclays | |
Citigroup | |
Baird | |
Leerink Partners | |
RBC Capital Markets | |
Goldman Sachs | |
Evercore ISI | |
KeyBanc Capital Markets | |
UBS | |
Deutsche Bank Securities | |
BofA Securities | |
Morningstar | |
Wells Fargo Securities | |
Jefferies & Co. | |
SVB Securities LLC | |
Nephron Research | |
JPMorgan Chase | |
Stifel Nicolaus | |
Credit Suisse | |
Cowen | |
Benchmark Company | |
Bernstein | |
B. Riley | |
Benchmark Capital |
EPS Revisions
- Stock Market
- Equities
- DHR Stock
- Consensus Danaher Corporation